SCHEMBL3757598

SCHEMBL3757598

COc1cccc(-c2cc(C(F)(F)F)c(C(=O)OC(C)(C)C)c(Cl)n2)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.39
GPBAR1 Q8TDU6 1/20 0.39
ADORA1 P30542 1/20 0.39
ALDH1A1 P00352 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DHODH Q02127 1/20 0.36
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MITF O75030 1/20 0.35
STAT3 P40763 1/20 0.35
HTT P42858 1/20 0.35
ADORA3 P0DMS8 2/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
ADORA2B P29275 1/20 0.35
PFKFB3 Q16875 1/20 0.35
ERN1 O75460 1/20 0.34
CYP3A4 P08684 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3752597 0.87 ADORA2A (0.41) ADORA2AGPBAR1ADORA1DHODHLMNA
SCHEMBL3752343 0.87 GPBAR1 (0.36) ADORA2AGPBAR1ADORA1ALDH1A1L3MBTL1
SCHEMBL3763504 0.80 AAK1 (0.39) ADORA2AGPBAR1ADORA1DHODHJAK2
SCHEMBL8202544 0.79 ALDH1A1 (0.35) GPBAR1ALDH1A1L3MBTL1LMNAHPGD
SCHEMBL3750094 0.77 ADORA2A (0.48) ADORA2AADORA1DHODHADORA3ADORA2B
SCHEMBL3747394 0.76 KMO (0.39) ADORA2AGPBAR1ADORA1DHODHLMNA
SCHEMBL13053995 0.76 ALDH1A1 (0.44) ALDH1A1L3MBTL1LMNAHPGDNPSR1
SCHEMBL3757830 0.73 CACNA1B (0.41) ALDH1A1L3MBTL1LMNANPSR1CYP2C9
SCHEMBL3747109 0.71 KDM4E (0.40) GPBAR1ALDH1A1LMNAHPGDKDM4E
SCHEMBL23943222 0.70 CD274 (0.46) ADORA2AADORA1ALDH1A1L3MBTL1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
WO-2008031501-A2 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF NAPRT, PNPO, FABP3 ADORA2A 509/4885GPBAR1 559/4885ADORA1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.